O

Oncogenes, 9

Oncogenic H-Ras signaling, 202 P

pl5INK4B, 12 pl6, 13

p21 transcription, 208

p21 and p27 partner switching, 208

p21WAF, 208

expression, 208 p27, 12

p53 status, 208, 267 Paclitaxel, 3, 138 Palmitoylated, 199 Palmitoylation, 22 pan-Ras antibody Y13-259, 92 PD083176, 104^105 PD169451, 106-113 PDGF, 212, 213

PDGF receptor tyrosine phosphorylation, 208

Pepticinnamin E, 153

Peptide mimetics, 4 Peptide substrate interaction with isoprenoid, 43 selectivity, 45 structure of, 41-44 Peptidic famesyltransferase inhibitors, 103-114 Peptidomimetics, 200, 201 Peptidomimetic inhibitors, 51—64

antitumor properties, 61-62 Pharmacodynamic, 7 Pharmacodynamic endpoints, 4, 7, 8 Pharmacokinetic, 7 Phenol-based FTIs, 55-56 Pl-3 kinase, 6

PI-3 kinase/AKT-2, 198, 207, 214, 215 Platelet-activating factor antogonist, 88 pRb, 208

phosphorylation, 215 Precipitation assays, 116-117 Preclinical, 7 Prelamin A, 89, 96 Prenylation, 16, 21 Preussomerin G, 153

Programmed cell death, 261, 264, 266, 269 Proliferation, 9 Protease, 22

Protein famesyltransferase

CaaX peptidomimetics, 225-230 farnesvl pyrophosphate analogs, 229 inhibitors, 225—230

effect on trvpanosomatid growth, 225— 230 '

in Leishmania spp., 225 purification, 223—224 substrate specificity, 223—225 in Trypanosoma brucei, 223—225 in Trypanosoma cruzi, 225 Protein prenylation, 212 in Giardia lambiia, 223 in Leishmania spp., 221-232 in Onchocerca volvulus, 223 in Plasmodium falciparum, 223 in Schistosoma mansoni, 223 structures of prenyl groups, 222 223 in Trypanosoma brucei, 221—232 in Trypanosoma cruzi, 221—232 in trypanoSomatids, 221—232 Proteomics, 5, 8 Purification, FTase, 116 PxF, 96

Pyrazine-bascd FTIs, 55—56 Pyridine-based FTIs, 60

Was this article helpful?

0 0

Post a comment